news | MaaT Pharma

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT033 is an oral formulation of MaaT Pharma’s full-ecosystem biotherapeutic characterized by high microbial diversity and richness Study will evaluate safety, dosing regimen and activity of MaaT033 in patients with acute myeloid leukemia receiving intensive chemotherapy Lyon,…

MaaT PharmaNovember 12, 2020

Press Releases

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

-- Clinical data was gathered from eleven patients with gastrointestinal (GI) aGvHD treated with MaaT013,…

MaaT PharmaAugust 31, 2020

Posters

Posters – EBMT 2020 Virtual

MaaT PharmaAugust 31, 2020

Press Releases

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

-- Data from the Company’s compassionate use program with MaaT013 as a treatment in patients…

MaaT PharmaAugust 28, 2020

Business Update

MaaT Pharma annonce le lancement d’une nouvelle campagne de collecte et de production pour son portefeuille de biothérapies à base de microbiome

La nouvelle campagne de collecte soutiendra le développement clinique futur du portefeuille de biothérapies à…

MaaT PharmaAugust 20, 2020

Business Update

MaaT Pharma Announces Initiation of New Collection and Manufacturing Campaign for its Microbiome Biotherapeutic Product Portfolio

New collection campaign to support future clinical development of microbiome biotherapeutic product portfolio and to…

MaaT PharmaAugust 20, 2020

Business Update

MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg

Lyon, France, July 16, 2020 – MaaT Pharma announced today the appointment of Claude Bertrand,…

MaaT PharmaJuly 16, 2020

Press Releases

MaaT Pharma Appoints Savita Bernal as Chief Business Officer

Lyon, France, May 28, 2020 – MaaT Pharma announced today that Savita Bernal, PhD, has…

MaaT PharmaMay 28, 2020

Press Releases

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international…

nboutaouiMay 12, 2020

Business Update

PR FDA Safety Alert

In response to the recent “FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation…

nboutaouiMarch 13, 2020

MaaT Pharma Treats First Acute Myeloid Leukemia Patient in Phase 1 Clinical Trial to Evaluate Capsule Formulation of Microbiome Restoration Biotherapeutic

MaaT Pharma Announces Positive Data for its Lead Microbiome Biotherapeutic MaaT013 in Intestinal Acute Graft-versus-Host-Disease at the Virtual 46th Annual Meeting of the EBMT

Posters – EBMT 2020 Virtual

MaaT Pharma to Announce Clinical Data with its Lead Microbiota Biotherapeutic in Intestinal Acute GvHD at Virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

MaaT Pharma annonce le lancement d’une nouvelle campagne de collecte et de production pour son portefeuille de biothérapies à base de microbiome

MaaT Pharma Announces Initiation of New Collection and Manufacturing Campaign for its Microbiome Biotherapeutic Product Portfolio

MaaT Pharma Appoints Claude Bertrand, Servier’s Executive Vice President of R&D, as Independent Board Member and Welcomes New Chief Medical Officer John Weinberg

MaaT Pharma Appoints Savita Bernal as Chief Business Officer

MaaT Pharma Announces Formation of Its GvHD-focused Scientific Advisory Board to Support Development of Microbiome Restoration Therapeutics in Hemato-oncological Indications

PR FDA Safety Alert

Categories

MAAT PHARMA

COMPANY

RESSOURCES

CONTACT